OSR Health, Inc. (OSRH)

Market Cap	3.97M -73.8%
Revenue (ttm)	1.71M -50.4%
Net Income	-10.22M
EPS	-0.31
Shares Out	35.12M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	57,166
Open	0.1200
Previous Close	0.1000
Day's Range	0.1000 - 0.1200
52-Week Range	0.0750 - 0.9000
Beta	0.65
Analysts	n/a
Price Target	n/a
Est. Earnings	Apr 1, 2027

About OSR Health

OSR Health, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Europe, and Korea. The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma completed phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the treatment of Wilms Tumor Protein (WT1); VXM08 for Carcinoembryonic antigen (CEA); and VXM10 for PD-L1. It is also developing design-augmented (DA) biologics comprising DRT-...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2020
• Employees: 22
• Stock Exchange: OTCMKTS
• Ticker Symbol: OSRH

Financial Performance

In 2025, OSR Health's revenue was $2.91 million, a decrease of -17.69% compared to the previous year's $3.53 million. Losses were -$18.01 million, 74.4% more than in 2024.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Nov 13, 2026

Data Sources Report a data error